Evidence map›Paper›PMID 29108474›Full record

ArticleThyroid : official journal of the American Thyroid Association2018

Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.

Sogol Mostoufi-Moab, Emmanuel Labourier, Lisa Sullivan, Virginia LiVolsi, Yimei Li, Rui Xiao, Sylvie Beaudenon-Huibregtse, Ken Kazahaya, N Scott Adzick, Zubair Baloch and 1 more

Open access · greenAbstract read
In one paragraph

Article in Thyroid : official journal of the American Thyroid Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Incidence ofThe Journal of international medical research · 2019
    Trial
  4. Evolving trends in pediatric thyroid nodules and cancer management.Annals of pediatric endocrinology & metabolism · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Approach to the Pediatric Patient With Thyroid Nodules.The Journal of clinical endocrinology and metabolism · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Molecular Landscape of Pediatric Thyroid Cancer: A Review.Diagnostics (Basel, Switzerland) · 2022
    Review
  18. Review
  19. Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Sogol Mostoufi-Moab1 Division of Oncology, The Children's Hospital of Philadelphia , Philadelphia, Pennsylvania.
Emmanuel Labourier2 Asuragen, Inc. , Austin, Texas.
Lisa Sullivan3 Division of Anatomic Pathology, Department of Pathology.
Virginia LiVolsi4 Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania.
Yimei Li5 Department of Biostatistics and Epidemiology, University of Pennsylvania , Philadelphia, Pennsylvania.
Rui Xiao5 Department of Biostatistics and Epidemiology, University of Pennsylvania , Philadelphia, Pennsylvania.
Sylvie Beaudenon-Huibregtse2 Asuragen, Inc. , Austin, Texas.
Ken Kazahaya6 Division of Pediatric Otolaryngology, Department of Pediatric Surgery, University of Pennsylvania , Philadelphia, Pennsylvania.
N Scott Adzick8 Division of General Surgery, Department of Pediatric Surgery, University of Pennsylvania , Philadelphia, Pennsylvania.
Zubair Baloch4 Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania.
Andrew J Bauer9 Division of Endocrinology and Diabetes, Department of Pediatrics, The Children's Hospital of Philadelphia , Philadelphia, Pennsylvania.
California University of Pennsylvania · USAsuragen (United States) · USChildren's Hospital of Philadelphia · USHospital of the University of Pennsylvania · US

Funding

Bone Deficits and Excess Adiposity after Pediatric Bone Marrow TransplantationK07CA166177 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MOSTOUFI-MOAB, SOGOL · 2013 to 2017
$825k
NCI NIH HHS K07 CA166177
6 · The paper itself

Abstract

backgroundThyroid nodules are less common in pediatric patients (i.e., those ≤18 years) than they are in adults. The Bethesda System for Reporting Thyroid Cytopathology allows for individual risk stratification, but a significant number of nodules are indeterminate. Incorporating gene mutation panels and gene expression classifiers may aid in preoperative diagnosis. The overall aim of this study was to assess the prevalence of oncogene alterations in a representative pediatric population and across a broad-spectrum of thyroid tumor diagnoses.

methodsThis was a retrospective cross-sectional evaluation of 115 archived samples, including: 47 benign (29 follicular adenoma, 11 diffuse hyperplasia, four thyroiditis, and three multinodular goiter), six follicular thyroid carcinomas (FTC), 24 follicular variant of papillary thyroid carcinomas (fvPTC), 27 classic variant of PTC (cPTC), eight diffuse sclerosing variant of PTC (dsvPTC), and three other PTC. Molecular testing was performed by multiplex qualitative polymerase chain reaction followed by bead array cytometry. Oncogene results were analyzed for association with age, sex, histology, lymph node metastasis, and intrathyroidal spread.

resultsA mutation in one of the 17 molecular markers evaluated was found in: 2/6 (33%) FTC, 8/24 (33%) fvPTC, 17/27 (63%) cPTC, and 4/8 (50%) dsvPTC. Mutations in RAS or PAX8/PPARG were exclusive to FTC and fvPTC. BRAF was the most common mutation in cPTC (12/17; 71%), and RET/PTC was the only mutation associated with dsvPTC. Overall, a mutation was found in 32/68 (47%) malignant specimens, with a single follicular adenoma positive for PAX8/PPARG. The relative distribution of gene alterations in pediatric lesions was similar to adults. The presence of a BRAF mutation in pediatric cPTC did not predict a more invasive phenotype.

conclusionsOf 33 nodules with genetic alterations, 32 were malignant. Mutations in RAS were most frequently associated with FTC, RET/PTC rearrangements with dsvPTC, and invasive fvPTC, and BRAF with cPTC. These results suggest a clinical role for mutational analysis of pediatric nodules to guide the surgical approach.

Indexed as

AdenomaAdolescentBiomarkers, TumorCarcinoma, PapillaryChildCross-Sectional StudiesDNA Mutational AnalysisFemaleGoiterHumansMaleProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Retrospective StudiesThyroid GlandThyroiditisBiomarkers, TumorHRAS protein, humanKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)oncogene testingpediatric thyroid cancer

Identifiers

PMID29108474
PMCPMC5770125
OpenAlexW2768001225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.